Kolistimetatnatrium Noridem (Colistimethate Sodium)

Colistimethate sodium is converted in the body to colistin, which binds to the lipopolysaccharide layer of Gram‑negative bacterial outer membranes. This binding disrupts membrane integrity, increases permeability, and leads to leakage of cellular contents, ultimately causing bacterial cell death.

The specific dose and treatment schedule for Kolistimetatnatrium Noridem are determined by the prescribing clinician based on the patient’s age, weight, severity of infection, and renal function. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Safety data for colistimethate sodium in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use during pregnancy or breastfeeding should only occur if the potential benefit justifies the potential risk, and it must be decided by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Kolistimetatnatrium Noridem (colistimethate sodium) is a polymyxin class antibiotic, distinct from aminoglycosides or beta‑lactams used for inhalation. It offers potent activity against multidrug‑resistant Pseudomonas aeruginosa, but carries a higher risk of nephro‑ and ototoxicity. Choice of therapy depends on bacterial susceptibility, patient tolerance, and clinical guidelines.

The inhalation solution should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures. Do not freeze. Once opened, use according to the label’s recommended period and discard any remaining solution after that time.

Kolistimetatnatrium Noridem is administered via a nebulizer or compatible inhalation device as directed by a healthcare professional. The patient inhales the solution, allowing the drug to reach the lower respiratory tract. Proper cleaning of the nebulizer and adherence to the prescribed schedule are essential for effectiveness.

Serious risks include anaphylactic reactions, severe bronchospasm, respiratory distress, hemoptysis, nephrotoxicity, and ototoxicity. Patients should be monitored for signs of allergic response, worsening breathing, or changes in kidney and hearing function, and the medication should be discontinued if any serious adverse event occurs.

Kolistimetatnatrium Noridem should not be used by individuals with a known hypersensitivity to colistin, polymyxin antibiotics, or any component of the formulation. It is also contraindicated in patients with severe renal impairment where alternative therapies are available, and caution is advised in pregnant or breastfeeding women until safety is established.